Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).
Junshik HongSoo-Mee BangYeung Chul MunHo-Young YhimJaehoon LeeHyeong-Seok LimDoyeun Ohnull nullPublished in: Journal of Korean medical science (2018)
In summary, IVIg-SN 10% formulation was found to be safe and effective in adult ITP patients (Trial registry at ClinicalTrials.gov, NCT02063789).